Arecor Therapeutics plc (AREC) ORD GBP0.01

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its in-house development programs include AT278, Oral GLP-1 and AT247. AT278 is its ultra-concentrated, ultra-rapid acting insulin candidate. AT278 is designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). AT247 is designed to accelerate the absorption of insulin post injection. It is focused on the development of an oral GLP-1 receptor agonist (semaglutide). It has partnered with TRx Biosciences, combining its Arestat technology and TRx Biosciences' lipid technology, Lipicore, to target improved bioavailability of an oral GLP-1 receptor agonist. Its partnered programs include AT220, AT292 and AT351.